IMI (LON:IMI – Get Rating) had its price target hoisted by Jefferies Financial Group from GBX 1,765 ($21.51) to GBX 1,870 ($22.79) in a research report released on Tuesday, Marketbeat reports. Jefferies Financial Group currently has a buy rating on the stock.
A number of other equities analysts also recently commented on IMI. Barclays reaffirmed an overweight rating and set a GBX 1,750 ($21.33) price objective on shares of IMI in a report on Tuesday, November 15th. Royal Bank of Canada raised their price objective on shares of IMI from GBX 1,900 ($23.16) to GBX 2,000 ($24.38) and gave the stock an outperform rating in a report on Friday, March 3rd. Finally, JPMorgan Chase & Co. lifted their price target on shares of IMI from GBX 1,655 ($20.17) to GBX 1,800 ($21.94) and gave the company an overweight rating in a report on Monday, March 6th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, IMI has an average rating of Buy and an average target price of GBX 1,855 ($22.61).
IMI Price Performance
LON:IMI opened at GBX 1,510 ($18.40) on Tuesday. The company has a 50-day moving average of GBX 1,503.27 and a 200-day moving average of GBX 1,342.73. The company has a market capitalization of £3.94 billion, a price-to-earnings ratio of 1,735.63, a PEG ratio of 1.12 and a beta of 1.17. IMI has a 52 week low of GBX 1,069 ($13.03) and a 52 week high of GBX 1,641 ($20.00). The company has a debt-to-equity ratio of 104.35, a quick ratio of 0.80 and a current ratio of 1.29.
IMI Increases Dividend
IMI Company Profile
IMI plc, a specialist engineering company, designs, manufactures, and services engineered products worldwide. The company operates through three divisions: IMI Precision Engineering, IMI Critical Engineering, and IMI Hydronic Engineering. The IMI Precision Engineering division develops motion and fluid control technologies for industrial automation, commercial vehicle, life sciences, energy, and rail applications.
See Also
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for IMI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMI and related companies with MarketBeat.com's FREE daily email newsletter.